Net Profit Margin: 8.70%
Is the net profit margin high or low?
The net profit margin of 8.70% is 20% below its 5-year average of 10.89%, near the low end of its 5-year range (4.33%–24.63%).
As of Friday, June 26, 2026. 2.51% below its 12-month average of 8.93%.
DGX Profit Margin
Reported quarterly profit margin; no daily interpolation.
DGX Average Net Profit Margin Chart
DGX Current vs Average Net Profit Margin Chart
DGX Net Profit Margin Metrics
NET PROFIT MARGIN
8.70%
NET PROFIT MARGIN AVG TTM
8.93%
NET PROFIT MARGIN AVG 3Y
8.99%
NET PROFIT MARGIN AVG 5Y
9.11%
NET PROFIT MARGIN AVG 10Y
9.60%
NET PROFIT MARGIN AVG 15Y
8.90%
NET PROFIT MARGIN AVG 20Y
8.89%
CURRENT VS TTM AVG
-2.51%
CURRENT VS 3Y AVG
-3.17%
CURRENT VS 5Y AVG
-4.40%
CURRENT VS 10Y AVG
-9.29%
CURRENT VS 15Y AVG
-2.22%
CURRENT VS 20Y AVG
-2.04%
DGX Competitors' Net Profit Margin
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Quest Diagnostics Incorporated (DGX) | $23.08B | 8.70% | 8.93% | 8.99% | 9.11% |
| BioNTech SE (BNTX)vs › | $23.07B | -44.73% | -31.89% | 3.77% | 12.08% |
| United Therapeutics Corporation (UTHR)vs › | $23.03B | 40.61% | 41.73% | 40.84% | 37.71% |
| Incyte Corporation (INCY)vs › | $22.73B | 26.71% | 12.90% | 13.00% | 12.11% |
| Labcorp Holdings Inc. (LH)vs › | $22.26B | 6.66% | 6.01% | 6.56% | 9.24% |
| Waters Corporation (WAT)vs › | $24.41B | 11.91% | 20.93% | 21.85% | 22.39% |
| West Pharmaceutical Services, Inc. (WST)vs › | $24.79B | 16.85% | 16.55% | 18.38% | 18.84% |
| STERIS plc (STE)vs › | $21.00B | 13.18% | 12.25% | 8.55% | 8.79% |
| Mettler-Toledo International Inc. (MTD)vs › | $25.54B | 21.40% | 21.94% | 21.74% | 21.20% |
| Moderna, Inc. (MRNA)vs › | $26.69B | -143.55% | -128.24% | -70.25% | -50.87% |
Margin Comparison
Operating Margin
14.3%
Net Profit Margin
8.7%
Net Profit Margin Formula & Definition
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Net Profit Margin FAQ
- What is the net profit margin for Quest Diagnostics Incorporated (DGX)?
- The net profit margin for DGX stock is 8.70%.
- Is Quest Diagnostics Incorporated's net profit margin high or low?
- The net profit margin of 8.70% is 20% below its 5-year average of 10.89%, near the low end of its 5-year range (4.33%–24.63%).
- What is the TTM average net profit margin for Quest Diagnostics Incorporated (DGX)?
- The TTM average net profit margin for DGX stock is 8.93%.
- What is the 3Y average net profit margin for Quest Diagnostics Incorporated (DGX)?
- The 3Y average net profit margin for DGX stock is 8.99%.
- What is the 5Y average net profit margin for Quest Diagnostics Incorporated (DGX)?
- The 5Y average net profit margin for DGX stock is 9.11%.
- What is the 10Y average net profit margin for Quest Diagnostics Incorporated (DGX)?
- The 10Y average net profit margin for DGX stock is 9.60%.
- What is the 15Y average net profit margin for Quest Diagnostics Incorporated (DGX)?
- The 15Y average net profit margin for DGX stock is 8.90%.
- What is the 20Y average net profit margin for Quest Diagnostics Incorporated (DGX)?
- The 20Y average net profit margin for DGX stock is 8.89%.
DGX Net Profit Margin History
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-03-31 | 8.70% |
| 2025-12-31 | 8.73% |
| 2025-09-30 | 8.70% |
| 2025-06-30 | 10.21% |
| 2025-03-31 | 8.30% |
| 2024-12-31 | 8.47% |
| 2024-09-30 | 9.08% |
| 2024-06-30 | 9.55% |
| 2024-03-31 | 8.20% |
| 2023-12-31 | 8.39% |
| 2023-09-30 | 9.80% |
| 2023-06-30 | 10.05% |
| 2023-03-31 | 8.67% |
| 2022-12-31 | 4.33% |
| 2022-09-30 | 10.22% |
| 2022-06-30 | 9.50% |
| 2022-03-31 | 13.56% |
| 2021-12-31 | 14.18% |
| 2021-09-30 | 18.13% |
| 2021-06-30 | 24.63% |
| 2021-03-31 | 17.21% |
| 2020-12-31 | 19.19% |
| 2020-09-30 | 20.32% |
| 2020-06-30 | 10.07% |
| 2020-03-31 | 5.43% |
| 2019-12-31 | 13.14% |
| 2019-09-30 | 10.94% |
| 2019-06-30 | 10.55% |
| 2019-03-31 | 8.62% |
| 2018-12-31 | 6.85% |
| 2018-09-30 | 11.22% |
| 2018-06-30 | 11.41% |
| 2018-03-31 | 9.34% |
| 2017-12-31 | 13.07% |
| 2017-09-30 | 8.29% |
| 2017-06-30 | 9.93% |
| 2017-03-31 | 8.58% |
| 2016-12-31 | 8.33% |
| 2016-09-30 | 10.08% |
| 2016-06-30 | 10.18% |
| 2016-03-31 | 5.53% |
| 2015-12-31 | 10.17% |
| 2015-09-30 | 18.09% |
| 2015-06-30 | 6.08% |
| 2015-03-31 | 3.32% |
| 2014-12-31 | 10.09% |
| 2014-09-30 | 6.72% |
| 2014-06-30 | 6.99% |
| 2014-03-31 | 5.90% |
| 2013-12-31 | 8.09% |
| 2013-09-30 | 22.61% |
| 2013-06-30 | 9.09% |
| 2013-03-31 | 7.56% |
| 2012-12-31 | 3.15% |
| 2012-09-30 | 8.77% |
| 2012-06-30 | 9.28% |
| 2012-03-31 | 8.19% |
| 2011-12-31 | 10.08% |
| 2011-09-30 | 9.01% |
| 2011-06-30 | 8.57% |
| 2011-03-31 | 7.73% |
| 2010-12-31 | 9.09% |
| 2010-09-30 | 10.62% |
| 2010-06-30 | 10.38% |
| 2010-03-31 | 9.00% |
| 2009-12-31 | 9.82% |
| 2009-09-30 | 10.13% |
| 2009-06-30 | 9.90% |
| 2009-03-31 | 9.24% |
| 2008-12-31 | 9.43% |
| 2008-09-30 | 6.06% |
| 2008-06-30 | 8.78% |
| 2008-03-31 | 7.82% |
| 2007-12-31 | -0.30% |
| 2007-09-30 | 5.54% |
| 2007-06-30 | 8.61% |
| 2007-03-31 | 6.94% |
| 2006-12-31 | 9.64% |
| 2006-09-30 | 10.14% |
| 2006-06-30 | 8.33% |
| 2006-03-31 | 9.30% |
| 2005-12-31 | 9.08% |
| 2005-09-30 | 9.86% |
| 2005-06-30 | 10.82% |
| 2005-03-31 | 9.97% |
| 2004-12-31 | 9.82% |
| 2004-09-30 | 10.09% |
| 2004-06-30 | 9.77% |
| 2004-03-31 | 9.25% |
| 2003-12-31 | 8.99% |
| 2003-09-30 | 9.83% |
| 2003-06-30 | 9.87% |
| 2003-03-31 | 8.06% |
| 2002-12-31 | 7.90% |
| 2002-09-30 | 8.18% |
| 2002-06-30 | 8.15% |
Related Metrics
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- James E. Davis